Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Top Cited Papers
Open Access
- 29 March 2023
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (6) , 755-768
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals
- Sanofi
This publication has 23 references indexed in Scilit:
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJournal of Clinical Oncology, 2019
- PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future DirectionsThe Oncologist, 2019
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 ProjectJournal of Thoracic Oncology, 2018
- Common pitfalls in statistical analysis: The perils of multiple testingPerspectives in Clinical Research, 2016
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology, 1998